CLINICAL_TRIALS
trial_result
· 2022-03-23
Clinical Trial Update: Gan & Lee Insulin Glargine Target Type (2) Evaluating Research [Phase 3]
Summary
Phase 3 clinical trial update for Gan & Lee Insulin Glargine targeting type 2 diabetes, completed with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gan and Lee Pharmaceuticals, USA | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2022-03-23